Research graph
References from The longer the better? Duration of corticosteroid treatment for mild immune-related pneumonitis. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Immune checkpoint therapy—current perspectives and future directions
10.1016/j.cell.2023.03.006 · 2023 · External reference
Immune-related adverse events associated with immune checkpoint blockade
10.1056/nejmra1703481 · 2018 · External reference
Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
10.1200/jco.2016.68.2005 · 2017 · External reference
Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis
10.1001/jamaoncol.2016.2453 · 2016 · External reference
Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy
10.1038/s41419-026-08440-7 · 2026 · External reference
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.001 · 2022 · External reference
10.1093/ajrccm/aamag349 · 2026 · Admitted local publication
Advances in the mechanisms, imaging characteristics and management strategies for immune checkpoint inhibitor-related pneumonitis
10.3389/fimmu.2025.1656063 · 2025 · External reference
Corticosteroids in oncology: use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper
10.1016/j.critrevonc.2022.103826 · 2022 · External reference
Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study
10.7326/m20-1594 · 2020 · External reference
